Stock Research: GlaxoSmithKline Pharmaceuticals

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

GlaxoSmithKline Pharmaceuticals

BSE:500660 INE159A01016
44
  • Value
    20
  • Growth
    46
  • Safety
    Safety
    73
  • Combined
    36
  • Sentiment
    54
  • 360° View
    360° View
    44
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company manufacturing, distributing, and trading in pharmaceuticals. The company operates in vaccines, specialty, and general medicine, with popular brands including Augmentin, Calpol, Shingrix, and Nucala. It operates primarily in India. In the last fiscal year, the company had 3113 employees, a market cap of $6242 millions, profits of $262 millions, and revenue of $439 millions.

more
Index
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 18-Dec-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
20 13 17 29
Growth
46 87 25 31
Safety
Safety
73 77 79 65
Sentiment
54 77 32 1
360° View
360° View
44 79 16 5
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
59 74 43 13
Opinions Change
50 94 50 50
Pro Holdings
n/a 54 77 49
Market Pulse
11 46 7 5
Sentiment
54 77 32 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
20 13 17 29
Growth
46 87 25 31
Safety Safety
73 77 79 65
Combined
36 77 19 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
18 19 12 20
Price vs. Earnings (P/E)
5 1 12 16
Price vs. Book (P/B)
5 5 10 7
Dividend Yield
70 56 74 76
Value
20 13 17 29
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
51 44 28 10
Profit Growth
47 92 45 88
Capital Growth
11 65 25 7
Stock Returns
83 77 71 53
Growth
46 87 25 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
92 92 90 82
Refinancing
17 18 26 22
Liquidity
92 92 92 80
Safety Safety
73 77 79 65

Similar Stocks

Discover high‑ranked alternatives to GlaxoSmithKline Pharmaceuticals and broaden your portfolio horizons.

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Fleury

BOVESPA:FLRY3
Country: Brazil
Industry: Health Care Services
Size: Medium
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Bosch

BSE:500530
Country: India
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The value case is weak (expensive and low Growth Rank), but sentiment is strong and financing is safe. This scenario may indicate future growth not yet in current financials. This is a speculative choice for investors with a high-risk appetite who are betting on the positive sentiment and safe financing to sustain a long-term turnaround.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: